Successful Treatment of Prosthetic Joint Infection due to Vancomycin-resistant Enterococci with Tedizolid.

about

Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.

P2860

Q33438834-F570D38E-52B9-4536-90BE-9A335A4B921D

P2860

Successful Treatment of Prosthetic Joint Infection due to Vancomycin-resistant Enterococci with Tedizolid.

Item

http://www.wikidata.org/entity/Q40243103

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Successful Treatment of Prosth ...... nt Enterococci with Tedizolid.

@en

type

Item

label

Successful Treatment of Prosth ...... nt Enterococci with Tedizolid.

@en

prefLabel

Successful Treatment of Prosth ...... nt Enterococci with Tedizolid.

@en

P1476

Successful Treatment of Prosth ...... nt Enterococci with Tedizolid.

@en

P2093

Maureen M Mercier

http://www.w3.org/2001/XMLSchema#string

Sheng Si

http://www.w3.org/2001/XMLSchema#string

Stephen Y Liang

http://www.w3.org/2001/XMLSchema#string

P2860

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections

Prosthetic-joint infections.

In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections.

Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.

Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.

Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006.

P304

105-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/IPC.0000000000000469

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael J Durkin

Melanie L Yarbrough

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28428726

http://www.w3.org/2001/XMLSchema#string

P932

5393450

http://www.w3.org/2001/XMLSchema#string

Successful Treatment of Prosthetic Joint Infection due to Vancomycin-resistant Enterococci with Tedizolid.

about

P2860

P2860

Successful Treatment of Prosthetic Joint Infection due to Vancomycin-resistant Enterococci with Tedizolid.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932